TY  - GEN
AU  - Robert,Caroline
AU  - Ribas,Antoni
AU  - Hamid,Omid
AU  - Daud,Adil
AU  - Wolchok,Jedd D
AU  - Joshua,Anthony M
AU  - Hwu,Wen-Jen
AU  - Weber,Jeffrey S
AU  - Gangadhar,Tara C
AU  - Joseph,Richard W
AU  - Dronca,Roxana
AU  - Patnaik,Amita
AU  - Zarour,Hassane
AU  - Kefford,Richard
AU  - Hersey,Peter
AU  - Zhang,Jin
AU  - Anderson,James
AU  - Diede,Scott J
AU  - Ebbinghaus,Scot
AU  - Hodi,F Stephen
TI  - Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
SN  - 1527-7755
PY  - 2019///0805
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Agents, Immunological
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Cohort Studies
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Melanoma
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Skin Neoplasms
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2017.75.6270
ER  -